December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Nitin Jain: Relapsed T-ALL remains a very challenging unmet need
Dec 5, 2024, 16:16

Nitin Jain: Relapsed T-ALL remains a very challenging unmet need

Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in ASH:

“Relapsed T-ALL remains a very challenging unmet need.

At ASH24 we report outcomes of a retrospective series of 12 pts who received nelarabine pegasparaginase and venetoclax as a treatment regimen

6/12 (50%) CR/CRh/CRi with many of these pts proceeding to allo-SCT

Work led by Niranjan Khaire.

A potential salvage option for R/R T-ALL.”

“Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL”

Authors: Niranjan Shivaji Khaire, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Nitin Jain et al.

Nitin Jain: Relapsed T-ALL remains a very challenging unmet need

More posts featuring Nitin Jain.

Dr. Nitin Jain is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, USA. He leads the CAR T program for the Leukemia Department, MDACC, and received the Leukemia and Lymphoma Society (LLS) Scholar in Clinical Research and Translational Research Program awards in 2022.

Specializing in acute and chronic leukemias, notably CLL and ALL, his research focuses on new drug development, reflected in his leadership of multiple investigator-initiated clinical trials.